[go: up one dir, main page]

DE60225694D1 - Fexofenadine hydrochlorid polymorph - Google Patents

Fexofenadine hydrochlorid polymorph

Info

Publication number
DE60225694D1
DE60225694D1 DE60225694T DE60225694T DE60225694D1 DE 60225694 D1 DE60225694 D1 DE 60225694D1 DE 60225694 T DE60225694 T DE 60225694T DE 60225694 T DE60225694 T DE 60225694T DE 60225694 D1 DE60225694 D1 DE 60225694D1
Authority
DE
Germany
Prior art keywords
fexofenadine hydrochloride
hydrochloride polymorph
polymorph
fexofenadine
bronchodilator
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60225694T
Other languages
English (en)
Other versions
DE60225694T2 (de
Inventor
Frederico Junquera Milla
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Texcontor
Original Assignee
Texcontor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Texcontor filed Critical Texcontor
Publication of DE60225694D1 publication Critical patent/DE60225694D1/de
Application granted granted Critical
Publication of DE60225694T2 publication Critical patent/DE60225694T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60225694T 2001-07-31 2002-07-29 Neues polymorph von fexo-fenadin Expired - Fee Related DE60225694T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01610081 2001-07-31
EP01610081 2001-07-31
PCT/IB2002/002954 WO2003011295A1 (en) 2001-07-31 2002-07-29 Fexofenadine polymorph

Publications (2)

Publication Number Publication Date
DE60225694D1 true DE60225694D1 (de) 2008-04-30
DE60225694T2 DE60225694T2 (de) 2008-06-26

Family

ID=8183555

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60225694T Expired - Fee Related DE60225694T2 (de) 2001-07-31 2002-07-29 Neues polymorph von fexo-fenadin

Country Status (7)

Country Link
US (2) US20040248935A1 (de)
EP (1) EP1414453B1 (de)
AT (1) ATE389405T1 (de)
DE (1) DE60225694T2 (de)
ES (1) ES2301662T3 (de)
PT (1) PT1414453E (de)
WO (1) WO2003011295A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002305162A1 (en) * 2001-04-09 2002-10-21 Teva Pharmaceutical Industries Ltd. Polymorphs of fexofenadine hydrochloride
AU2003248657A1 (en) * 2002-06-10 2003-12-22 Teva Pharmaceutical Industries Ltd. Polymorphic form xvi of fexofenadine hydrochloride
GB0319935D0 (en) 2003-08-26 2003-09-24 Cipla Ltd Polymorphs
MXPA06012281A (es) * 2004-04-26 2007-07-18 Teva Pharma Formas cristalinas de clorhidrato de fexofenadina y procesos para su preparacion.
ITMI20041143A1 (it) * 2004-06-08 2004-09-08 Dipharma Spa Polimorfi di fexofenadina e procedimento per la loro preparazione
WO2007052310A2 (en) * 2005-11-03 2007-05-10 Morepen Laboratories Limited Polymorphs of fexofenadine hydrochloride and process for their preparation
DOP2006000274A (es) 2005-12-14 2007-10-15 Sanofi Aventis Us Llc Formulación de suspensión de fexofenadina
MX2009000320A (es) * 2006-07-11 2009-06-05 Mutual Pharmaceutical Co Formulaciones de liberacion controlada.
US20090306135A1 (en) 2008-03-24 2009-12-10 Mukesh Kumar Sharma Stable amorphous fexofenadine hydrochloride
US20100183717A1 (en) * 2009-01-16 2010-07-22 Kristin Arnold Controlled-release formulations
US9216955B2 (en) 2010-06-15 2015-12-22 Chemelectiva S.R.L. Polymorphic form of Fexofenadine hydrochloride, intermediates and process for its preparation
CN104072402B (zh) * 2014-07-16 2016-08-17 昆山龙灯瑞迪制药有限公司 一种新结晶形式的盐酸非索非那定化合物及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1178041A1 (de) * 1994-05-18 2002-02-06 Aventis Pharmaceuticals Inc. Verfahren zur Herstellung von wasserfreien und Hydrat-Formen von antihistaminischen Piperidinderivaten
KR100405116B1 (ko) * 1995-02-28 2004-02-05 아벤티스 파마슈티칼스 인크. 피페리디노알칸올화합물에대한약제학적조성물

Also Published As

Publication number Publication date
EP1414453B1 (de) 2008-03-19
WO2003011295A1 (en) 2003-02-13
EP1414453A1 (de) 2004-05-06
ATE389405T1 (de) 2008-04-15
US20100010229A1 (en) 2010-01-14
WO2003011295B1 (en) 2003-04-03
PT1414453E (pt) 2008-05-29
DE60225694T2 (de) 2008-06-26
ES2301662T3 (es) 2008-07-01
US20040248935A1 (en) 2004-12-09

Similar Documents

Publication Publication Date Title
ATE454138T1 (de) Tablette mit modifizierter freisetzung von bupropion hydrochlorid
WO2005110410A3 (en) Kinase inhibitors as therapeutic agents
DK1506185T3 (da) Forbindelser og deres anvendelse som 5-HT-inhibitorer
GB0124627D0 (en) Novel compounds
MXPA05009367A (es) Antagonistas del receptor opioide.
DE60210944D1 (de) N-substituierte heterocyclische nichtaryl-nmda/nr2b-antagonisten
WO2005074603A3 (en) Aminobenzoxazoles as therapeutic agents
NO20040933L (no) Nye gamma-sekretaseinhibitorer.
NO20042811L (no) Substituerte henzoksazoler og analoger som estrogene midler
DK1613304T3 (da) DPP-IV-inhibitorer
ATE478049T1 (de) Phosphodiesterase-4-inhibitoren, einschliesslich n-substituierter diarylaminanaloga
ATE308522T1 (de) Opioidrezeptorantagonisten
MXPA05007609A (es) Antagonista de un receptor sensible al calcio.
DK1421075T3 (da) Piperidinderivater, der er nyttige som CCR5-antagonister til behandling af HIV
SE0101932D0 (sv) Pharmaceutical combinations
ATE389405T1 (de) Fexofenadine hydrochlorid polymorph
IS7305A (is) HIV-integrasa tálmar
HRP20090159T1 (en) Use of glucosidase inhibitors for therapy of mucovisidosis
EA200801199A1 (ru) Ингибиторы киназы
NO20054787D0 (no) Indenderivater som farmasotiske midler
IL172542A0 (en) 2-hydroxymethyl-3,4,5-trihydroxy-1-benzilpiperidine derivatives as inhibitors of glucosylceramide
DK1814848T3 (da) 2,3,4-substitueret-cyclopentanoner som terapeutiske midler
WO2009106599A3 (en) Substituted piperidines as therapeutic compounds
WO2003037916A3 (en) Linear basic compounds having nk-2 antagonist activity and formulations thereof
WO2004048381A3 (en) Pyrazoloazepine compounds as pharmaceutical agents

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee